Kornimate/medical-research-clean huggingface dataset:
whole body vibration in obese female students

Conditions: Obesity

Summary: obesity is a global public-health issue, with rising incidence and prevalence, significant expenditures, and poor results. obesity has become a worldwide epidemic in both developed and underdeveloped countries. a body mass index (bmi) of 30 kg/m2 is required for class i obesity, a bmi of 35 - 39.9 kg/m2 is required for class ii obesity, and a bmi of 40 kg/m2 is required for class iii obesity (morbidly obese). obesity will be the likely situation for the majority of the adult population during the next two decades due to an abundance of calorie-rich food and apathy toward exercise.

obese and overweight young people swayed at a higher rate than people of normal weight. two hypotheses have been offered to explain the negative effect of weight on balance control. the first is decreased plantar sensitivity as a result of hyper-activation of plantar mechanoreceptors caused by the constant pressure of supporting a heavy burden. the second theory is that there is a higher mechanical demand owing to the big body mass itself, as well as a non-negligible amount of body mass further away from the axis of rotation (i.e., ankle joint in an inverted pendulum model) that creates a higher gravitational torque. as a result, in order to maintain an upright posture, the gravitational torque that accelerates the body must be opposed by muscle torques. wbv is a mechanical stimulation characterized by oscillatory motion supplied from a platform to the entire body. the current devices employ two distinct systems: (a) a vertical vibration, in which the entire plate oscillates uniformly up and down with only a vertical translation; and (b) reciprocating vertical displacements on the left and right sides of a fulcrum, which increases the lateral accelerations. wbv training includes biomechanical characteristics such as body position, amplitude, frequency, magnitude, and duration.

Eligibility criteria:
inclusion criteria: * female students * bmi ≥ 30 * aged from 18 to 25 years old exclusion criteria: * pregnancy * musculoskeletal disorders * history of spinal surgery * epilepsy * medications that could affect the musculoskeletal system * performing regular exercise of more than 3 times a week * metal plates in the body * ligament sprain * medical history such as cardiovascular disease, or diabetes mellitus

Keywords: whole body vibration trunk endurance balance obesity females
valproate versus topiramate in migraine

Conditions: Migraine Disorders

Summary: investigators aim to compare the effect of valproate versus topiramate in migraine by assessing the reduction in mmd in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency.

investigators will enroll 600 migraine patients who are diagnosed according to ichd3-beta criteria in our study and will use a questionnaire to detect their demographic and clinical features (disease duration, attack frequency, and duration, pain intensity assessed by the visual analogic scale and we have two groups the first group will include 300 patients and will receive 500-1000mg valproate daily and acetaminophen 500-1000 mg in acute attack, and the second group will receive topiramate100 mg per day and acetaminophen 500-1000 mg in acute attack for at least three months. investigators will assess the number of migraine days after three months of treatment and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14).. hit-6 score reduction in each group after three months of treatment. the safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (teae) in patients through regular follow-up procedures for three months.

Eligibility criteria:
inclusion criteria: naive migraine patients, according to the international classification of headache disorders 3rd edition, aged 18-75 years, exclusion criteria * patients with major neurological disorders such as ( epilepsy, ischemic or hemorrhagic stroke, multiple sclerosis, mitochondrial diseases, brain tumors, and patients with essential tremors. * patients with major systemic diseases such as malignancy, collagen, liver, and renal diseases. * patients with cardiovascular diseases like hypertension (systolic blood pressure of more than 130 and/or diastolic blood pressure of more than 85 mm/hg on at least three different occasions, diabetes (fasting plasma glucose level \>126 mg/dl and/or a casual plasma glucose \>200 mg/dl and/or hba1c more than 6.5. * patients with valvular and ischemic heart diseases, bradycardia or heart blocks, congestive heart failure patients who received prophylactic treatment for migraine, patients with any contraindications to drugs used in the study patients with topiramate or valproate contraindications.

Keywords: topiramate valproate migraine
rct comparing 21 and 22 g needle in the diagnosis of sarcoidosis by ebus tbna

Conditions: Sarcoidosis

Summary: randomized controlled trial to determine the efficacy of different needles sizes (22g and 21g) used in endobronchial ultrasound guided transbronchial needle aspiration

among the bronchoscopic techniques in diagnosis of sarcoidosis, transbronchial needle aspiration (tbna) of lymph nodes has emerged as a particularly useful supplement to the previously known endobronchial and transbronchial biopsies. the efficacy and safety of conventional tbna is well established. with improvements in technology, the last decade has seen the use of convex probe endobronchial ultrasonography (ebus) to guide tbna under direct vision. this technique is a minimally invasive alternative to mediastinoscopy, further it offers additional advantage of choosing the appropriate node for sampling on the basis of their echogenicity. studies subsequently have demonstrated the superiority of ebus tbna over conventional tbna. once the role of tbna in diagnostic bronchoscopy was established, technical aspects of the procedure became the topic of research. needle size used in tbna is one such important factor. apparently, larger the needle, better the tissue yield and hence improved diagnostic capability. conventional tbna is usually performed with a 19g needle, though varying sizes have been used in different studies (18, 21, 22, 26g). on the other hand, ebus-tbna is performed with a 22g needle. more recently 21g needles are being used for the same purpose. there have been conflicting reports in literature, when these two needle sizes have been compared with regards to the adequacy of the sample, accuracy of diagnosis and the rate of complications. moreover, the above studies undertaken so far were done from centers where malignancy was the predominant diagnosis. whether the needle size used during ebus tbna has any impact on diagnosing benign diseases like sarcoidosis is still not clear, hence this study was planned. the investigators hypothesize that performing ebus-tbna using 21g needles may enable identification of intact compact granulomas in sarcoidosis, and hence a better diagnostic yield than using a 22g needle.

Eligibility criteria:
inclusion criteria: * age ≥18 years * clinicoradiological suspicion of sarcoidosis where endobronchial ultrasound guided transbronchial needle aspiration is contemplated * enlarged hilar and mediastinal lymph nodes \>10 mm (any axis) on computed tomography of the chest exclusion criteria: * hypoxemia (spo2 \<92%) on inspired fraction of oxygen 0.3 * treatment with systemic glucocorticoids for more than 2 weeks in the preceding three months * diagnosis of sarcoidosis possible with another minimally invasive technique such as skin biopsy or peripheral lymph node biopsy * failure to provide informed consent
prevalence of sars -cov2 carriage in asymptomatic and mildly-symptomatic children

Conditions: Covid19

Summary: this study is expected to provide, for the first time, data on cov2-sars circulation in asymptomatic children and children with moderate respiratory symptoms in order to construct the severity pyramid of this novel pathogen. this information will be essential in the coming weeks to understand the dynamics of the transmission of this pathogen at the population level and to highlight the relevance of public health interventions, particularly with regard to the systematic closure of schools and childcare facilities.

cov2-sars is an emerging respiratory virus of the coronavirus family responsible for a global epidemic since november 2019. as of march 10, 2020, it had caused more than 160,000 cases of corona virus disease (covid-19), including more than 6,500 deaths worldwide. france is one of the main epidemic outbreaks with more than 5,000 confirmed cases and the number of diagnosed patients is increasing every day. the number of confirmed paediatric cases is relatively low, and the mortality rate in children is close to zero. this contrast suggests that children are more likely to present pauci-symptomatic or even asymptomatic forms of the disease, which are therefore undiagnosed in most cases. given the rapid spread of this virus, and the fact that indigenous cases without an obvious chain of transmission now appear to be frequent in france, it is possible that the pauci-symptomatic or asymptomatic child may play a role in the transmission of the pathogen and the dynamics of the epidemic, as documented for other respiratory pathogens such as influenza. based on this hypothesis, the closure of children's communities has been organized in france and other highly endemic countries.

Eligibility criteria:
inclusion criteria: * asymptomatic children: * age between birth and 15 years * carrying out a visit within the framework defined by the learned societies and professional organisations representative of paediatrics in france, i.e. : * the consultation of the first month and all consultations involving compulsory vaccinations (2, 4, 5, 11, 12, 16 months). * consultations for acute pathologies, infectious or not. * monitoring of chronic diseases that warrant clinical examination (the majority of which can be carried out by telemedicine) or in the case of acute exacerbation. * in one of the participating outpatient centres * during the study period * with a clinical examination that does not reveal any progressive infectious pathology and pauci-symptomatic children * age between birth and 15 years, * consultant at one of the participating outpatient centres * during the study period * and presenting with a mild respiratory infection: * rhinopharyngitis, acute otitis media, angina, bronchitis, etc. * acceptance to participate in the protocol by one of the holders of parental authority * affiliated to a social security exclusion criteria: * refusal to participate in the study

Keywords: sars-cov2 rhino-pharyngeal carriage primary care children
social convoy palliative care (convoy-pal) mobile health for older adults

Conditions: Chronic Conditions, Multiple

Summary: the aim of this study is to test the feasibility and usability of the convoy-pal mobile intervention among older adults. the study is a pilot waitlist control rct with 40 patients and their convoys randomized to one of two arms: convoy-pal intervention or waitlist control. feasibility will be assessed by recruitment, attrition, and data collection on measures of quality of life and social support. usability will be captured by self-report usability scales and actual back end utilization data.


Eligibility criteria:
inclusion criteria: * ≥65 years of age * self-report diagnosis of heart failure (hf) * have multiple chronic conditions (mcc) based on the disease burden/morbidity assessment by self-report (individuals will be eligible if they self-report the number of diagnosis \> 2 and a disease burden score \>2 indicating the presence of at least two chronic conditions that limit activities of daily of living) * community dwelling in the united states * english speaking exclusion criteria: * self-reported diagnosis of alzheimer's disease or dementia * self-reported diagnosis of a severe mental health problem (e.g. schizophrenia, bipolar affective disorder or other psychotic illness) * participation in community-based palliative care in the last 12 months
non-invasive testing to evaluate wound healing in diabetes

Conditions: Diabetic Foot Ulcer

Summary: normal group: we will collect normative data from healthy individuals to include baseline data, screening, and images. up to 500 people will be enrolled and can include normal healthy volunteers, staff and students/trainees. data will be collected one time with no follow up. patient group: we will prospectively collect data using one instrument (camera) (snapshotnir, kent imaging, calgary, alberta, canada). we will collect non-contact imaging data before surgeries, during surgeries (if feasible), and during follow-up clinic visits. we will collect vascular data, demographic medical history, wound characteristics and measurements, frequency of debridement, off-loading, and clinic visits from existing medical records. we will collect lab data such as cultures glycosylated hemoglobin, hemoglobin and hematocrit, esr, crp and egfr obtained per standard of care. imaging with this device is research-only.

this is a prospective, observational study. all medical and surgical care provided to the patient group will be standard of care. patient group: once a patient is identified as requiring vascular intervention or lower extremity ulceration (includes lower extremity wound of any cause, a surgical incision, a flap or graft) and consent to participation, their lower extremity will be imaged. they will be imaged preop, intraop (if feasible) and on post-op day 1 + or - 7 days if they require surgery and for each surgery related to the ulceration. they will also be imaged once a month in follow up for up to a total of 6 months or healing of the wound, determined by study physician. normal group: the normal group will have one-time imaging and data collection. the kent instrument does not touch the patient and is being evaluated to measure perfusion to predict wound healing, flap survival and amputation level healing. they are research only and not standard of care, and are not being used to determine care in the patient group.

Eligibility criteria:
investigator patients inclusion criteria: * patient of the investigators * diagnosis of diabetes mellitus * one or more moderate to severe diabetic foot ulcers/infections * 18-89 years of age exclusion criteria: * non-diabetic * is pregnant or plans to become pregnant * is nursing or actively lactating * developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including untreated schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years. * active alcohol or substance abuse in the opinion of the investigator that could impair the subject's ability to provide informed consent, participate in the study protocol or record study materials * patients with a history of poor compliance normal healthy volunteers inclusion criteria: * over 18 * have a foot exclusion criteria: * foot wounds * non-english speaking
a trial of dalotuzumab in combination with irinotecan versus cetuximab and irinotecan for participants with metastatic rectal cancers (mrc) (mk-0646-025)

Conditions: Rectal Neoplasms

Summary: the purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with intravenous (iv) dalotuzumab (mk-0646) + irinotecan therapy relative to participants treated with iv cetuximab + irinotecan. the primary hypothesis is that administration of dalotuzumab in combination with irinotecan to participants with wild-type kras metastatic rectal carcinoma with high insulin growth factor (igf)-1/low igf-2 expression levels improves progression-free survival compared to patients treated with cetuximab in combination with irinotecan.


Eligibility criteria:
inclusion criteria: * has metastatic colorectal cancer with primary tumor originating from the rectum * has an available archival (recent or remote) tumor, or newly obtained formalin-fixed tissue available for analysis for biomarker studies * has at least one measurable lesion greater than or equal to 10 mm * disease has progressed after treatment with both irinotecan- and oxaliplatin-containing regimens and should have progressed on or within 3 months of completing their last line of therapy * has a performance status 0-1 on the eastern cooperative oncology group (ecog) performance scale exclusion criteria: * has poorly-controlled diabetes * has received chemotherapy or biological therapy within 2 weeks prior to initial dosing on this study, or whose toxicities from agents administered 2 weeks earlier have not resolved to at least grade 1 or baseline, or who is within 3 weeks from a prior surgery * has received radiotherapy within 2 weeks prior to initial dosing on this study, unless the radiotherapy was for management of pain * is currently participating or has participated in a study with an investigational compound or device within 30 days or 5 half-lives of the investigational agent, whichever is longer, of initial dosing on this study * was unable to complete previous course of irinotecan due to intolerable toxicity, other than discontinuation due to fatigue following prolonged administration (\>4 months exposure) * has prior exposure to insulin-like growth factor 1 receptor (igf-1r) inhibitors or epidermal growth factor receptor (egfr) inhibitors * has a known central nervous system (cns) metastases and/or carcinomatous meningitis * has primary cns tumor * has a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma; potentially curative therapy with no evidence of that disease for 5 years, deemed low risk for recurrence by treating physician. * is human immunodeficiency virus (hiv)-positive * has active hepatitis b or c infection and is receiving antiviral treatment regimens * has symptomatic ascites or pleural effusion * is concurrently using growth hormone (gh), or growth hormone inhibitors
flex - long-term extension of fit (fracture intervention trial)(0217-051)

Conditions: Osteoporosis, Postmenopausal

Summary: this study was conducted among women who had previously received alendronate for 3 to 6 years during the fracture intervention trial (fit). participants in the flex study were randomly assigned to receive alendronate (either 5 or 10 mg/day) or matching placebo during the next 5 years, in order to evaluate the effects of continuing or discontinuing alendronate treatment on bone mineral density and biochemical markers of bone turnover.


Eligibility criteria:
inclusion criteria: * to be eligible to participate in this study, women needed to have previously participated in the fracture intervention trial (fit) and to have been part of the group treated with alendronate in fit * they needed to have received at least 3 years of treatment with alendronate in the fit trial * in addition, their bone mineral density (bmd) at the hip needed to be better than it was at the start of fit exclusion criteria: * patients were excluded if they had conditions that contraindicated alendronate therapy and if they might have used other medications for the treatment of osteoporosis * women were also excluded if bmd at the hip was below a certain level (t-score \<=-3.5); that is, if it were 3.5 standard deviations or more lower than the average for young adult women
the effects azd8529 on cognition and negative symptoms in schizophrenics

Conditions: Schizophrenia

Summary: the purpose of this study is to assess if azd8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of schizophrenia or schizoaffective disorder exclusion criteria: * ect in the last 6 months * substance abuse or dependence * history of claustrophobia

Keywords: schizophrenia early phase trials
the use of topical anaesthetic in the banding of internal haemorrhoids

Conditions: Hemorrhoids

Summary: the investigators' aim is to assess if they can complete a study measuring the effect of local anaesthetic gel (instillagel) on reducing pain experienced by patients undergoing a common treatment for haemorrhoids (piles). this treatment is called rubber band ligation and is commonly performed in the investigators'clinics.

a feasibility trial assessing patient recruitment, retention, randomization, and surgeon acceptability of topical anaesthetic use during rubber band ligation of haemorrhoids. a patient and assessor blinded feasibility trial. the trial population will prospectively be recruited from colorectal surgery outpatients. patients will be randomized to two groups to receive: lubricating gel (k-y jelly) and topical anaesthetic gel (instillagel) or lubricating gel alone (the standard care). the intervention group will receive lubricating gel and topical anaesthetic gel (containing lidocaine active ingredient) administered rectally, whilst the control group will receive lubricating gel alone (standard care). this will be carried out in colorectal outpatients. the band ligation of the haemorrhoids should occur between 5-10 minutes after administration of the topical anaesthetic/lubricating gel. pain scores and the use of oral analgesia will be measured immediately after the procedure (5 minutes), upon leaving the clinic (approximately 30 minutes after), at 4 hours, and 72 hours following the procedure. vasovagal symptoms or other complications will be recorded whilst the patient is in the clinic. at 1 month post procedure, patients will be phoned to determine if any adverse events have occurred.

Eligibility criteria:
inclusion criteria: * symptomatic grade 1-3 haemorrhoid disease, 18+ years old, english is the first language. exclusion criteria: * allergy to active ingredients of instillagel, allergy to local anaesthetic, chronic liver disease, grade 4 haemorrhoid disease, pregnancy, inflammatory bowel disease, pre-existing anorectal disease.

Keywords: haemorrhoid banding topical anaesthetic
therapeutic eus registry

Conditions: Gastrointestinal Disease

Summary: the purpose of this prospective registry is to assess long-term data on efficacy, safety and clinical outcome of therapeutic endoscopic ultrasound (t-eus) . the registry will evaluate technical feasibility, clinical outcome, safety profile and overall clinical management through medical chart review. the procedures we are evaluating are all clinically indicated and will not be prescribed to someone to participate in this research study.

this study is a prospective, observational, medical chart review. there will be a retrospective chart review for patients who underwent endoscopic suturing procedures from october 2014 - may 2019. those subjects will undergo no additional tests and procedures as part of this study. in order to validate these procedures and broaden its use beyond tertiary centers, it is crucial to understand its efficacy and success rate. the objective of the study is to evaluate retrospectively and prospectively the efficacy and safety of t-eus procedures.

Eligibility criteria:
inclusion criteria: * any patient who has undergone clinically indicated and/or standard of care t-eus procedures from october 2014 - may 2019 * any patient who will undergo clinically indicated and/or standard of care t-eus procedures from june 2019 - june 2027 exclusion criteria: * any patient who has not undergone endoscopic ultrasound would be excluded from the study. * below 18 years of age